Does race play a role in thyroid disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Race Does Play a Significant Role in Thyroid Disease Presentation and Outcomes

Yes, race significantly influences thyroid disease epidemiology, presentation patterns, and clinical outcomes, though these differences reflect social determinants of health and healthcare disparities rather than biological differences.

Key Racial Differences in Thyroid Disease Epidemiology

Subclinical Hypothyroidism

  • The prevalence of subclinical hypothyroidism in Black patients is one-third that of White patients 1
  • Among patients with elevated TSH levels, approximately 75% have values below 10 mIU/L 1
  • In White women over 60 years, prevalence reaches up to 20% 1

Subclinical Hyperthyroidism

  • Subclinical hyperthyroid disease is more common in Black patients than White patients 1
  • This contrasts with the hypothyroidism pattern, showing race affects different thyroid conditions differently
  • Overall prevalence is 3.2% when TSH lower limit is <0.4 mIU/L 1

Critical Disparities in Thyroid Cancer

Presentation and Disease Severity

Black patients present with more advanced and aggressive thyroid disease compared to White patients:

  • Black patients are more likely to not receive recommended surgical resection (adjusted OR 1.10,95% CI 1.02-1.20) 2
  • Black patients have longer time to surgical referral and present with more severe benign disease 3
  • When presenting for benign thyroid surgery, Black patients have:
    • More compressive symptoms (45.0% vs 21.2%, p<0.01) 3
    • Larger thyroid glands (median 71g vs 24.3g) 3
    • Longer disease duration before referral 3

Mortality Disparities

Black patients have significantly higher all-cause mortality from thyroid cancer (adjusted HR 1.19,95% CI 1.07-1.31) 2

Critically, socioeconomic status explains 48.7% of the difference in thyroid cancer-specific mortality between Black and White patients (indirect effect HR 1.07,95% CI 1.01-1.14) 2. This is the most important finding—the disparities are not biological but rather driven by social determinants of health.

Surgical Outcomes

Black patients experience worse postoperative complications:

  • Higher risk of neck hematoma (OR 2.32,95% CI 1.51-3.55) 4
  • Higher risk of recurrent laryngeal nerve injury (OR 1.97,95% CI 1.53-2.55) 4
  • Asian patients also have elevated RLN injury risk (OR 1.88,95% CI 1.15-3.06) 4

Paradoxical Findings in Malignancy Rates

Interestingly, thyroid cancer is less prevalent in Black patients undergoing thyroidectomy (24.0% vs White 52.1%, Hispanic 58.7%, Asian 71.7%) 5, and when present, shows:

  • Less extrathyroidal extension (9.7% vs White 18.6%) 5
  • Less nodal involvement (12.4% vs White 31.1%) 5
  • Less lateral neck metastasis (4.4% vs White 10.8%) 5

This paradox—lower cancer rates but worse outcomes—suggests selection bias and delayed access to care rather than protective biological factors.

Clinical Implications and Pitfalls

Common Pitfalls to Avoid

  1. Do not assume race represents biological risk—the 2023 AAP framework emphasizes race is a social construct 6
  2. Do not delay referral based on race—Black patients already experience longer times to surgical evaluation 3
  3. Screen more aggressively for access barriers in minority patients given the 48.7% contribution of socioeconomic factors to mortality disparities 2

Actionable Clinical Approach

When evaluating thyroid disease across racial groups:

  • Maintain high clinical suspicion in Black patients despite lower subclinical hypothyroidism prevalence
  • Expedite surgical referrals for minority patients to prevent presentation with advanced disease
  • Address socioeconomic barriers including insurance status, transportation, and health literacy
  • Monitor surgical outcomes more closely in Black and Asian patients given higher complication rates
  • Recognize that Hispanic patients present with more advanced thyroid cancer (higher extrathyroidal extension rates) 5

The Evidence Quality

The guideline evidence 1 from JAMA (2004) provides the epidemiologic foundation, while recent research 2, 7 from 2024-2025 demonstrates persistent disparities in outcomes. The mediation analysis 2 is particularly robust in quantifying how much socioeconomic factors explain mortality differences—this is the highest quality evidence addressing the mechanism of racial disparities.

The most recent 2025 ATA guidelines 8 do not specifically address racial disparities in their management recommendations, representing a gap in guideline development that clinicians must bridge with the research evidence showing clear differences in presentation, treatment access, and outcomes.

References

7
Research

Racial and Ethnic Disparities in the Diagnosis and Treatment of Thyroid Disease.

The Journal of clinical endocrinology and metabolism, 2024

8
Research

2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.

Thyroid : official journal of the American Thyroid Association, 2025

Related Questions

What is the appropriate evaluation and management for a 15 mm thyroid nodule in an adult?
Is laser hair removal of the neck safe for a healthy 30‑year‑old man, and are there any thyroid or other contraindications?
In a 51-year-old woman with frequent cough suggestive of bronchitis and a history of thyroid cancer, when should a chest radiograph be performed?
Why do I develop anxiety after taking my morning levothyroxine (Synthroid) dose—75 micrograms four days a week and 88 micrograms one day a week—following a thyroidectomy for papillary carcinoma performed six years ago, and how should I adjust my dosing regimen?
Given my history of total thyroidectomy and radioactive iodine for papillary thyroid carcinoma six years ago, a low‑normal TSH of 0.877 mIU/L, and a rising serum thyroglobulin from 0.9 to 2.7 ng/mL, does this indicate recurrent disease and would further TSH suppression lower the thyroglobulin level?
What does a FRAX hip fracture risk of 13% over ten years indicate and how should it be managed?
Do magnetic resonance imaging (MRI) scans involve ionizing radiation or only magnetic fields?
Can I switch directly from zopiclone 7.5 mg to trazodone for insomnia?
Should lithium be tapered over one week or two weeks at each dose reduction step?
Which regions does the vertebral artery supply?
How does testosterone therapy affect the severity of obsessive‑compulsive disorder (OCD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.